Travoprost

CAS 157283-68-6 12 current records 3 historicalSmall Molecule

Who holds supplier records for Travoprost? 12 organisations hold a current record for Travoprost: an active US FDA Type II Drug Master File. A further 3 organisations have only historical (inactive) DMF filings. Recorded organisation countries for current records: India (3), Taiwan (2), Czechia (1), Argentina (1) and 4 other countries (4); not recorded for 1.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Travoprost: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/travoprost

Reading the evidence

  • 12 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 5 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Travoprost expires 14 Feb 2031. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (12)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Travoprost. Country is the organisation's recorded country, not necessarily the manufacturing site.

  • CHIROGATE INTERNATIONAL INC
    Active DMF 32964, 22738 · latest filing Jul 2018
    Taiwan
  • CAYMAN PHARMA SRO
    Active DMF 22289 · latest filing Dec 2008
    Czechia Company GMP cert on record
  • DELTA BIOTECH SA
    Active DMF 26180 · latest filing Jun 2012
    Argentina
  • Dr. Reddy's Laboratories Ltd.
    Active DMF 14890 · latest filing May 2000
    India Company GMP cert on record
  • EUROAPI HUNGARY LTD
    Active DMF 29418, 34742 · latest filing Dec 2020
    Hungary
  • GENTEC SA
    Active DMF 34370 · latest filing Jan 2020
    Belgium
  • Lupin Limited
    Active DMF 26878 · latest filing Apr 2013
    India Company GMP cert on record
  • MSN Laboratories Private Limited
    Active DMF 27863 · latest filing Jan 2014
    India Company GMP cert on record
  • SCINOPHARM TAIWAN LTD
    Active DMF 23423 · latest filing Dec 2009
    Taiwan
  • VERANOVA LP
    Active DMF 22088 · latest filing Oct 2008
    United Kingdom
  • YS LIFE SCIENCE CO LTD
    Active DMF 24907 · latest filing Apr 2011
  • Zhejiang Ausun Pharmaceutical Co., Ltd.
    Active DMF 40018 · latest filing May 2024
    China Company GMP cert on record
Need Travoprost sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Historical records (3)

Organisations whose Type II DMFs for Travoprost are no longer active. These show a past filing, not current supply.

Show all 3 historical records

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (9 listed products contain Travoprost). The latest listed patent expires 14 Feb 2031. The latest listed exclusivity runs to 13 Dec 2026. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Travoprost is a prostaglandin analog used for reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It works by increasing the outflow of aqueous humor from the eyes.

Chemical identity

IUPAC name
propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate
Canonical SMILES
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@H](C[C@H]([C@@H]1/C=C/[C@H](COC2=CC=CC(=C2)C(F)(F)F)O)O)O
InChIKey
MKPLKVHSHYCHOC-AHTXBMBWSA-N
Synonyms
Travatan API, al-6221, duotrav component travoprost, idose tr, izba, nsc-760366, otx-tp, travatan

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Prostaglandin Analog
Chemical structure
Prostaglandins

Therapeutic areas

Ophthalmology

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Travoprost?

12 organisations hold an active US FDA Type II Drug Master File or a CEP for Travoprost: CHIROGATE INTERNATIONAL INC (Taiwan), CAYMAN PHARMA SRO (Czechia), DELTA BIOTECH SA (Argentina), Dr. Reddy's Laboratories Ltd. (India), EUROAPI HUNGARY LTD (Hungary), GENTEC SA (Belgium), Lupin Limited (India) and MSN Laboratories Private Limited (India), and 4 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Travoprost Drug Master Files are active?

CHIROGATE INTERNATIONAL INC (DMF 32964, 22738), CAYMAN PHARMA SRO (DMF 22289), DELTA BIOTECH SA (DMF 26180), Dr. Reddy's Laboratories Ltd. (DMF 14890), EUROAPI HUNGARY LTD (DMF 29418, 34742), GENTEC SA (DMF 34370), Lupin Limited (DMF 26878) and MSN Laboratories Private Limited (DMF 27863) and 4 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Travoprost records mean?

3 organisations have only inactive Type II DMFs for Travoprost. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does the FDA Orange Book list patents for products containing Travoprost?

Yes. The latest patent listed for an approved US product containing Travoprost expires 14 Feb 2031, across 9 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Travoprost supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Travoprost?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.